Pioneering Acute Omega-3 Therapeutics

THDG3: A Novel Omega-3 FA Molecule

Formulated as an emulsion

Administered IV as an acute therapeutic agent

Excellent safety profile

Strong intellectual property (6 issued patents)

 

THDG3: Potential Clinical Indications

STROKE: A debilitating disease & a large unmet need

17M people worldwide suffer a stroke every year

~ 80% of strokes are ischemic

Less than 8% of patients receive t-PA (the only FDA approved drug)

Direct and indirect costs estimated to be $102B/year,  and projected to be $240B by 2030 (in the US alone)

 

Acute Injection of THDG3 in Stroke Models

 

  Potential to Revolutionize Stroke Pharmacotherapy

Lipid based, novel

class of molecules endogenous in the brain

Pleiotropic mechanisms of action (as against single targets)

Safe and well tolerated class of molecules in humans

High degree of efficacy in pre-clinical models (up to 90% infarct reduction)

Proven, long therapeutic window, ensuring greater brain tissue salvage

New & now available “imaging based selection” of stroke patients

About Us

Suman Lal

CEO
MD, MSc, PhD, MBA

suman@decktherapeutics.com

Richard Deckelbaum

Founding Scientist & Chair SAB

MD, CM, FRCP(C)

rjd@decktherapeutics.com

The science behind DeckTherapeutics originated from the laboratory of Dr. Richard Deckelbaum, Director of the Institute of Human Nutrition, Professor of Pediatrics and of Epidemiology, Robert R. Williams Professor of Nutrition at the Columbia University, New York. Dr. Deckelbaum has published over 400 research and other publications, co-edited a number of books, chaired task forces for the American Heart Association, the European Atherosclerosis Society, the Institute of Medicine, the March of Dimes, and has served on advisory committees of the National Institutes of Health, RAND Corporation, and of the U.S.A. National Academies of Science. He has also held advisory roles relating to clinical applications of lipids with several major nutrition and pharmaceutical companies. He served on the Food and Nutrition Board of the National Academies of Science, and is a Senior Fellow of the Synergos Institute. Dr. Deckelbaum’s laboratory has been funded for over 30 years (more than $45 million) by NIH and other grants focusing on triglyceride emulsions, lipid metabolism, and omega-3 fatty acids.

 

© 2019 by DECKTHERAPEUTICS Inc.